Young-Jae Yang

Title: Young-Jae Yang: Innovator in Antibody-Drug Conjugates

Introduction

Young-Jae Yang is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates (ADCs). His work focuses on innovative solutions for treating diseases associated with the over-expression of ROR1, a protein linked to various cancers.

Latest Patents

Young-Jae Yang holds a patent for an antibody-drug conjugate that targets human ROR1. This invention encompasses new ADCs, their active metabolites, and methods for their preparation. The patent outlines the uses of these ADCs in the treatment and prevention of illnesses, specifically those related to ROR1 over-expression, such as cancer. The invention includes a pharmaceutical composition that comprises an antibody binding to ROR1 or an antigen-binding fragment thereof.

Career Highlights

Throughout his career, Young-Jae Yang has worked with notable companies in the biotechnology sector. He has been associated with Legochem Biosciences, Inc. and Abl Bio Inc., where he has contributed to advancing research and development in therapeutic solutions.

Collaborations

Young-Jae Yang has collaborated with esteemed colleagues, including Yun-Hee Park and Ho Young Song. Their joint efforts have furthered the understanding and application of antibody-drug conjugates in medical treatments.

Conclusion

Young-Jae Yang's innovative work in antibody-drug conjugates represents a significant advancement in cancer treatment. His contributions continue to impact the field of biotechnology and offer hope for effective therapies against challenging diseases.